Clinical Trial Update: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating Lutetium-177 dotatate in slowly progressive Grade 1-2 advanced midgut neuroendocrine tumors. The study is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Midgut Neuroendocrine Tumor

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | Phase 3 | Status: RECRUITING